RNASET2 Biomarker Stratification for Severe IBD Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective diagnostic tools for stratifying inflammatory bowel disease (IBD) patients into subgroups for targeted therapeutics and predicting disease severity, particularly in identifying patients who may benefit from anti-TL1A therapy.
Innovation Solution
Utilizing RNASET2 as a biomarker, along with TL1A and IFN-γ, to diagnose IBD severity and select appropriate therapeutic strategies, including anti-TL1A therapy, by analyzing genetic variants and expression levels in patient samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for IBD, then general diagnosis can be performed, but prediction of disease severity and therapy response is ineffective
Solution Approach 1:
The patent segments the homogeneous IBD patient population into distinct subgroups based on RNASET2 expression levels, genetic variants, and methylation status. This segmentation enables precise prediction of disease severity and therapy response by analyzing specific molecular characteristics rather than treating all patients uniformly, thereby improving measurement precision for disease prognosis.
Solution Approach 2:
The patent performs preliminary molecular characterization of patients using RNASET2 expression analysis, genetic variant detection, and methylation assessment before initiating therapy. This preliminary action identifies patients at high risk for severe disease or poor therapy response in advance, allowing for proactive treatment stratification and personalized therapy selection before clinical deterioration occurs.
2Reliability
If targeted therapy selection is implemented using molecular biomarkers, then treatment outcomes improve, but diagnostic complexity increases
Solution Approach 1:
The patent employs a multi-functional diagnostic approach where RNASET2 expression analysis serves multiple purposes: it predicts disease severity, identifies patients at risk for poor therapy response, and stratifies patients for targeted therapy selection. This universal biomarker reduces the need for multiple separate complex assays, as a single RNASET2-based test provides comprehensive prognostic and predictive information across different clinical scenarios.
Solution Approach 2:
The patent uses RNASET2 expression levels, genetic variants, and methylation status as intermediary molecular markers that mediate between complex biological pathways and clinical outcomes. These intermediaries simplify the diagnostic process by providing measurable, quantifiable indicators that reflect underlying disease mechanisms and therapy response potential, making complex biological information accessible through standardized assays.
Data Source
AI summary
The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-γ. The invention further provides a process for patient identification and/or stratification.